CN109172624A - A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis - Google Patents
A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis Download PDFInfo
- Publication number
- CN109172624A CN109172624A CN201811304617.7A CN201811304617A CN109172624A CN 109172624 A CN109172624 A CN 109172624A CN 201811304617 A CN201811304617 A CN 201811304617A CN 109172624 A CN109172624 A CN 109172624A
- Authority
- CN
- China
- Prior art keywords
- weight
- pharmaceutical composition
- arterial thrombosis
- parts
- cerebral arterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Vascular Medicine (AREA)
Abstract
The present invention provides a kind of pharmaceutical composition for treating cerebral arterial thrombosis, including Dioscin, arasaponin, Gardenoside, different american pokeweed root leaf and seed phenol A, the parts by weight of the Dioscin are 8-15, the parts by weight of arasaponin are 6-12, the parts by weight of Gardenoside are 6-12, the parts by weight of different american pokeweed root leaf and seed phenol A are 6-12, and described pharmaceutical composition can be used for improving since cerebral ischemia causes the therapeutic effect of cerebral injury.The pharmaceutical composition derives from natural drug, and all medicine compatibilities are synergistic, and drug activity significantly improves, and prepares simply, has very high potentiality to be exploited.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions and its application for treating cerebral arterial thrombosis, belong to Natural Medicine Chemistry skill
Art field.
Background technique
Cerebral arterial thrombosis has become the number one killer of human health.Cerebral apoplexy belongs to cranial vascular disease, due to certain or
Certain reasons cause thrombosis, cerebrovascular blocking, and brain microcirculation is destroyed, and cerebral insufficiency eventually leads to brain cell
Impaired, cerebral function is destroyed.With the raising of people 's material life level, more sugar, fat etc. are taken in, in addition not being good for
The life style of health, the number for suffering from cranial vascular disease gradually increases and increasingly rejuvenation, has become threat human health,
Cause the first disabled and dead killer.According to statistics, our national Cerebral Haemorrhage Invasion Rates and the death rate are the first in the world, wherein
About 94% cerebral apoplexy burden is caused by controllability risk factor.Its risk factor mainly include blood pressure, blood glucose, cholesterol levels,
Smoking, constitutional index, diet and physical exertion etc..However effective therapy there is no for headstroke.It is clinically mostly used at present early
Phase thromboembolism treatment, but bring is cerebral ischemia re-pouring injured simultaneously, it is same to endanger patient.Currently, cerebral arterial thrombosis
Treatment method is very limited, since pharmaceutical composition has synergistic effect with interaction between each ingredient, and has more targets
The action character of point makes it have very big advantage in terms of prevent and treat cerebral arterial thrombosis, therefore needs one kind from " prevent, mend, control "
Various aspects are multi-pronged, improve cerebral injury caused by cerebral ischemia in time, and can reach the work for preventing and treating cerebral arterial thrombosis
With.
Summary of the invention
The technical problem to be solved by the present invention is to overcome the deficiencies of existing technologies, provides and a kind of treat cerebral arterial thrombosis
Pharmaceutical composition, with good prevention and treatment effect, and bulk pharmaceutical chemicals are in liberal supply.
In order to solve the above technical problems, the present invention provides a kind of pharmaceutical composition for treating ischemia apoplexy, including potato
Chinese yam saponin(e, arasaponin, ginsenoside Rb1, different american pokeweed root leaf and seed phenol A, it is characterised in that: the parts by weight of the Dioscin are
8-15, the parts by weight of arasaponin are 6-12, and the parts by weight of Gardenoside are 6-12, the parts by weight of different american pokeweed root leaf and seed phenol A
For 6-12.
The parts by weight of the Dioscin are 10-12, and the parts by weight of arasaponin are 8-10, the weight of Gardenoside
Number is 8-10, and the parts by weight of different american pokeweed root leaf and seed phenol A are 8-10.
One or more of solution, tablet, capsule, pill and granule can be made in the composition.
The composition further includes the pharmaceutically auxiliary material in allowed band, and the auxiliary material includes binder in tablet, fills out
Fill agent, disintegrating agent, lubricant, preservative, antioxidant, corrigent, aromatic, cosolvent, emulsifier, solubilising in liquid preparation
Auxiliary material used in agent, osmotic pressure regulator etc. and capsule, pill and granule.
The arasaponin the preparation method comprises the following steps: take appropriate notoginseng decoction piece, it is dry to be crushed to after constant weight, then with steaming
It evaporates water boiling and extraction three times, merges decocting liquid, being concentrated into relative density is 1.10g/ml, it filters, macroporous absorbent resin on filtrate,
With flow velocity 3-5BV/h by chromatographic column (BV column volume), when absorption reaches equilibrium state, at least ten column volume is washed, is removed
Remove water-solubility impurity.Finally, flow velocity is 1-2 BV/h with 60% ethanol water isocratic elution of 5-8 times of column volume, collection is washed
De- liquid, is concentrated into no alcohol taste, and 50-60 DEG C of vacuum drying obtains thick arasaponin.Thick arasaponin powder 100mg is taken, it is molten
In 60% ethanol water, the arasaponin solution that concentration is 2mg/ml is made, flows through cation exchange resin column and connects
Into anion-exchange resin column, flow velocity is 1-2 BV/h by chromatographic column, elution 3-5 times is repeated, finally with 10 times of column volumes
The elution of 60% ethanol water, collect eluent and be concentrated into no alcohol taste, 50-60 DEG C of vacuum drying, the Radix Notoginseng for obtaining high-purity is total
Saponin(e.
The cation exchange resin is D72, in anion exchange resin D201, D296, D280, Dt, Gt, Ds
Any one.
The ratio of the cation exchange resin and anion exchange resin is 1 ︰ 1.
Application of the pharmaceutical composition in treatment cerebral arterial thrombosis.
Described pharmaceutical composition is for the Drug combination with anti-cerebral ischemia, for improving hypertension, hyperlipidemia, glycosuria
Cerebral arterial thrombosis therapeutic effect caused by disease.
Dioscin belongs to the different spirostane alcohol type derivative in steroid saponin, be various plants medicine active material and
Quality Control ingredient, and the clinically main constituents and Quality Control ingredient of many Chinese patent drugs and Chinese medicine compound prescription.Dioscin is potato
The main active of Chinese yam section plant, Dioscin rich content in dioscorea nipponica, Dioscorea Panthcica Chinese yam, dioscorea zingiberensis wright, has
Platelet aggregation-against and thrombosis effect, prompt it with cerebral protection.Modern pharmacology research shows Dioscin also
There are Cardiovascular regulation, anti-inflammatory, antitumor and other effects.
Radix Notoginseng also known as pseudo-ginseng are China's tradition rare Chinese medicines, have dissipating stasis and stanching bleeding, detumescence ding-tong and other effects.The total soap of Radix Notoginseng
Glycosides (PNS) is the effective active composition of Radix Notoginseng, containing main components such as ginsenoside Rb1, ginsenoside Rg1, notoginsenoside Rs,
Its preparation such as XUESHUANTONG ZHUSHEYE and XUESAITONG ZHUSHEYE are widely applied in the prevention and treatment of cardiovascular and cerebrovascular disease.Modern study table
Bright, with improving, myocardial ischemia, antithrombotic, anti-inflammatory, anti-oxidant, anti-atherogenic is hard in cardiovascular and cerebrovascular disease for arasaponin
Change, inhibit cranial nerve cell apoptosis, improving cerebral ischemia and improve various effects such as energetic supersession.
Chinese medicine cape jasmine is the dry mature fruit of madder wort cape jasmine (Gardenia jasminoides Ellis),
Former plant is mainly distributed on the ground such as Fujian China, Jiangxi, Zhejiang, Hunan, Anhui, Taiwan.Cape jasmine first recorded in Shennong's Herbal,
Middle product are classified as, cold in nature, taste is slightly sour and bitter, and it is nontoxic, have effects that purging intense heat relieving restlessness, reducing fever and causing diuresis and removing pattogenic heat from the blood and toxic material from the body.It is main
Ingredient is Gardenoside (geniposide), also known as geniposide, belongs to iridoid glycoside constituents, and aglycon is Geniposide.
Modern pharmacology research shows that Gardenoside has the effects that anti-inflammatory, liver protection, anti-oxidant, in recent years to it in treatment cerebrovascular disease
Disease, as there has also been certain researchs for Cerebral ischemia protection and treatment Alzheimer's disease etc..
Different american pokeweed root leaf and seed phenol A is extracted from the seed of Phytolaccaceae plant american pokeweed root leaf and seed (Phytolacca americana),
The neuronal cell cultures experiment of suckling rat brain hemisphere shows that different american pokeweed root leaf and seed phenol A can improve choline acetyl in brain cell culture medium and turn
The activity of enzyme is moved, to have neurotrophic effect.
Different Phytolacca acinosa phenol A all has very strong antioxidant activity, but its auxiliary therapeutic action to cerebral arterial thrombosis, there is not yet
Relevant report.
Advantageous effects of the invention:
Composition provided by the present invention can be obviously improved Neuroscore, reduce cerebral ischemic model compared with model group
Brain water content improves the pyknosis of ischemic region neuron, oedema that rats with cerebral ischemia occurs, and a large amount of inflammatory cells occur, and nerve is fine
Tie up fenestral fabric, a large amount of nerve cell apoptosis, the pathomorphisms such as disappearance；Platelet aggregation rate and thrombus weight can be reduced, is extended
It is the clotting time of cerebral ischemic model, preferable with high dose group effect.Can illustrate from the above experimental result: the present composition is to big
Every instruction of the cerebral arterial thrombosis model of mouse, all has improvement and therapeutic effect.
Therefore, a kind of composition provided by the present invention can have the function that prevent and treat cerebral arterial thrombosis.And
And composition of the invention is from a wealth of sources, and it is readily available, so being developed as phases such as food additives, health food and drugs
Product is closed, there is very high potentiality to be exploited.
Specific embodiment
The content of present invention is not limited only to the content of the respective embodiments described above, the group of one of them or several specific embodiments
The purpose of invention also may be implemented in contract sample.
Beneficial effects of the present invention are verified by following embodiment:
Embodiment 1
The parts by weight of Dioscin are 8, and the parts by weight of arasaponin are 6, and the parts by weight of Gardenoside are 6, different US business
The parts by weight of land phenol A are 6, above each compound are mixed, oral administration solution is made in emulsification.
Embodiment 2
The parts by weight of Dioscin are 10, and the parts by weight of arasaponin are 8, and the parts by weight of Gardenoside are 9, different US business
The parts by weight of land phenol A are 10, tabletting after magnesium stearate mixes are added in above each compound, tablet is made.
The present invention can also be prepared by the way that the dosage forms such as tablet, capsule and pill are made in the pharmaceutical composition
Its drug effect is verified at solution, and by following pharmacodynamic test.
Effect experiment example 1
Therapeutic effect of the present composition to cerebral arterial thrombosis rat
Healthy SD adult rat, male, cleaning grade, weight 300-350g, by Heilongjiang University of Chinese Medicine's drug safety evaluation
The heart (GLP) provides, and animal uses credit number: SCXK2014-004, room temperature raising, drinking-water of freely ingesting.
KDC-160HR high speed freezing centrifuge (Keda Innovation Co., Ltd)；BL-420F biological functional system
(Chengdu TME Technology Co., Ltd.)；AL204 electronic balance (plum Teller-support benefit instrument Shanghai Co., Ltd)；LBY-NJ2
Platelet aggregation instrument (Pulisheng Instruments Co., Ltd., Beijing)；DK-98-11A electric heating constant-temperature water-bath tank (Tianjin Stettlen instrument
Co., Ltd)；KDC-160R high speed refrigerated centrifuge (Zhong Jia branch company of Keda Innovation Co., Ltd).
(tablet, mouth is made in composition of the invention by a kind of pharmaceutical composition for treating cerebral arterial thrombosis of the invention
Clothes.6~8g, 2~3 times on the one, or follow the doctor's advice.), positive drug Folium Ginkgo is (oral.Every 9.6mg containing total flavonoids,
Terpene lactone 2.4mg.One time 2,3 times a day, or follow the doctor's advice.Shijiazhuang Yi Ling medicine company has limited liability company's production).
60 SD rats, which are fed, adapts to environment after a week, 3.5% chloraldurate intraperitoneal injection of anesthesia (35mg/ of rat
100g weight), it separates bilateral common carotid arteries and ligatures, concrete operations are as follows: rat dorsal position is fixed on operating table, is routinely disappeared
Poison, neck median incision, exposure right carotid and external carotid artery, the vagus nerve of careful separation and arteria carotis communis companion's row,
Arteria carotis communis and external carotid artery are ligatured with 5/0 silk thread, it is small arteria carotis communis is cut one with eye scissors apart from crotch 0.5cm or so
Siding bolt is sent into notch, inwardly carries out, by line bolt along arteria carotis communis internal carotid direct motion to middle artery, encounter resistance by notch
Stop when power, calculates insertion depth (1.8 ± 0.5) cm from arteria carotis communis crotch, intraluminal middle cerebral artery occlusion in rats blood supply is caused to block；
Sham-operation group, which is only performed the operation, does not ligature arteria carotis communis, steams again raising after post-operative wound suture.Experiment and raising room temperature are
25℃.Postoperative 4h comments part according to nervous function, and the successful rat of model is grouped at random by weight, is divided into model group, sham-operation group,
Positive drug control group, present composition high and low dose group, guarantee that every group of successful number of animals of modeling is 10 by totally 5 groups.It makes
The 2nd day beginning gastric infusion is treated 14 days after mould, and present composition high and low dose group is big with 0.5g/kg, 0.25g/kg respectively
Mouse weight gastric infusion, one time a day, positive drug control group give Folium Ginkgo 0.54/kg rat body weight gastric infusion, model group
Same amount of normal saline is given with sham-operation group.Postoperative 4 hours, administration mid-term and administration latter stage press following standard using mono blind method
Groups of animals nervous symptoms are observed, behavior integration scoring is carried out.Sacrificed by decapitation animal when last dose 1h takes out rapidly brain group
It knits, every takes 70 DEG C of bakings in half brain one thousandth electronic balance weighing postposition baking oven for 24 hours, to claim dry brain weight after cooling,
Calculate separately brain water content.When last dose 1h, broken end takes brain, and every takes half brain to be fixed with formaldehyde, and paraffin section carries out
Conventional H E dyeing, optical microphotograph microscopic observation each group rat cerebral tissue structure change.
Neurological score measurement: standards of grading: 0 point: impassivity functional impairment symptom；L points: slight focal nerve function
Energy defect mentions tail vacantly not tensible left side fore paw；2 points: the focal neurologic impairment of moderate is walked turn to the left at once
Circle；3 points: the focal neurologic impairment of severe, i.e., walking is tired and topples over to the left；4 points: spontaneous cannot walk, it is not intended to know or
Stupor；0 point, 4 defend oneself the failure of bright model, 1-3 defends oneself bright model success, and 2-3 defends oneself bright for stable model.
According to appraisal result, mid-term and administration latter stage, the scoring and model group of each administration group is administered in postoperative 4h model success
More statistically significant, each administration group all has improvement result to the nervous function of cerebral arterial thrombosis.Comparison among groups are examined with t
Test expression, as a result with± s is indicated.It the results are shown in Table 1.
Influence of 1 present composition of table to rat nerve function
Note: compared with model group,*P < 0.05,#P < 0.01.
Brain water content measurement
Brain water content measures, and collagen tissue oedema situation after observable cerebral ischemia is calculated: water content with following formula
(%)=(weight in wet base-dry weight)/weight in wet base × 100%.Comparison among groups with t examine indicate, as a result with± s is indicated.It the results are shown in Table 2.
Compared with blank group, brain water content obviously increases model group, the high agent of the present composition in each administration group
Amount group can obviously reduce brain water content.
Influence of 2 present composition of table to rat cerebral tissue's water content
Note: compared with blank group,*P < 0.05, compared with model group,#P < 0.05
Histopathology morphological observation
Normal group: brain tissue neuronal cell morphology is still regular, no cell infiltration and a small amount of hyperemia.
Model group: the visible bleeding peripheral region neuron pyknosis of ischemic region, oedema, a large amount of inflammatory cells occur, and center is visible
Fenestral fabric is presented in nerve fibre, and a large amount of nerve cell apoptosis disappear.
Treatment group: present composition high and low dose group is compared with model group, and neuronal cell morphology is more regular, apoptosis
Quantity significantly reduces, and the rare nerve fibre fenestral fabric in center, inflammatory cell significantly reduces, and oedema degree is substantially reduced, with
Normal group compares no significant difference, and high dose group is better than low dose group.
Effect experiment example 2:
Influence of the present composition to cerebral arterial thrombosis rat platelet aggregation function
LBY-NJ2 platelet aggregation instrument
Experimental group modeling and administration are the same.
When last dose 1h, 3.5% chloraldurate intraperitoneal injection of anesthesia of animal (35mg/ 100g weight) opens abdominal cavity, from
Inferior caval vein take blood 2.5ml be put into plus 3.8% sodium citrate test tube in, by anticoagulant whole blood with 1000rmin-1 from
Heart 8min prepares rich platelet slurry (PRP), is placed in the Eppedorf pipe of 0.5ml and closes lid preservation, it is spare to set constant temperature hole；It is remaining
Lower anticoagulation is using supernatant obtained by 3000rmin-1 centrifugation 10min as platelet poor plasma (PPP).Upper Instrument measuring obtains blood platelet
Aggregation rate.Comparison among groups with t examine indicate, as a result with± s is indicated.It the results are shown in Table 3.
Model group platelet aggregation rate increases, and the present composition has downward effect, especially high dose to platelet aggregation rate
The effect of amount group is obvious.
Influence of 3 present composition of table to platelet aggregation
Note: compared with blank group, * P < 0.01, compared with model group, 0.01 ## P < 0.05 of #P <
Effect experiment example 3:
Influence of the present composition to thrombosis in carotid body
When last dose 1h, rat is surveyed by literature method with 3.5% chloraldurate intraperitoneal injection of anesthesia (35mg/ 100g weight)
Silk thread wet weight of thrombus in left common carotid artery and right vena jugularis externa conduit.Comparison among groups with t examine indicate, as a result with± s is indicated.
It the results are shown in Table 4.
Experimental result
Thrombus weight and the obvious increase of blank group of model group, the thrombus weight of each treatment group of the present composition is obvious to be lowered,
The effect of especially high dose group is more obvious.
Influence of 4 present composition of table to thrombus
Note: compared with blank group, * P < 0.01, compared with model group, # < 0.05
Effect experiment example 4:
Influence of the present composition to the clotting time
Experimental group modeling and administration are the same.
When last dose 0.5h, with capillary in taking a pipe blood in rat eye socket, the clotting time is recorded.Comparison among groups t
Examine indicate, as a result with± s is indicated.It the results are shown in Table 5.
The clotting time of model group is obviously shortened, statistically significant compared with blank group, after present composition treatment
The cruor time extending of each group, high dose group have statistical significance compared with model group.
Influence of 5 present composition of table to the clotting time
Note: compared with blank group, * P < 0.05, compared with model group, #P < 0.05
Each administration group of the present invention can be obviously improved Neuroscore compared with model group, reduce the brain tissue of cerebral ischemic model
Water content improves the pyknosis of ischemic region neuron, oedema that rats with cerebral ischemia occurs, and a large amount of inflammatory cells occur, nerve fibre grid
Shape structure, a large amount of nerve cell apoptosis, the pathomorphisms such as disappearance；Platelet aggregation rate and thrombus weight can be reduced, cerebral ischemia is extended
It is the clotting time of model, preferable with high dose group effect.Can illustrate from the above experimental result: the present composition lacks rat
Every instruction of hemorrhagic cerebral apoplexy model, all has improvement and therapeutic effect.
Embodiment 3
Clinical trial
Clinical data and method
Case selection
Patient 103 for choosing cerebral arterial thrombosis disease are used as research object, are randomly divided into two groups.Wherein, treatment group 52,
Age at 45 ~ 70 years old, average age (61.32 ± 6.13) year；Control group 51, the age at 45 ~ 70 years old, average age (63.42
± 6.11) year.Two groups of patient's general information include gender, age, symptom etc. without significant difference (P > 0.05), are had comparable
Property.
It is included in standard and exclusion criteria
It is included in standard: meeting the cerebral apoplexy apoplex involving the channels and collaterals patient of diagnostic criteria；7 points≤National Institutes of Health cerebral apoplexy amount
Table (NIHSS) scores≤22 points；Age 45~70 years old；15~30 d of the course of disease.Exclusion criteria: the course of disease is more than 30 d；Progressivity brain
Bleeding patients after stroke, lacunar infarction, transient ischemic attack, cerebral infarction；The heart diseases such as rheumatic heart disease, coronary heart disease merge
Atrial fibrillation induces cerebral embolism patient；There is stroke history and leaves sequelae person；Merge serious liver kidney, hemopoietic system and metabolism system
Unite disease patient；Phrenoblabia or advanced dementia person.
Treatment method
Treatment group takes orally a kind of Chinese medicine composition for treating cerebral arterial thrombosis of the invention, takes orally, 3 times a day, the course for the treatment of 1
Month.Control group takes orally Folium Ginkgo, one time 2,3 times a day, the course for the treatment of 1 month.Or it follows the doctor's advice.Shijiazhuang Yi Ling medicine company has share
Co., Ltd's production.
Criterion of therapeutical effect and treatment results
Using " clinical neurologic deficit of stroke patients degree standards of grading " (hold the 4th time of nineteen ninety-five Chinese Medical Association
Cerebrovascular disease academic conference), according to scale NIHSS scoring after, according to integral improve situation, according to formula: (pre-treatment score is commented
Point-post treatment integral scoring) scoring of/pre-treatment score × 100% calculated, commenting for comprehensive therapeutic effect is carried out in conjunction with disability degree
Fixed: be almost recovered: neurological deficits score reduces 91%~100%, and disability degree is 0 grade；It is effective: neurological deficits score
46%~90% is reduced, disability degree is 1~3 grade；Effective: neurological deficits score reduces 18%~45%；It is invalid: nervous function
Defect scoring reduces≤17% or increases；Two groups after Comprehensive Clinical curative treatment 30 days, treatment group's overall clinical efficacy rate (90.
38%, it is almost recovered 30, effective 9, effective 8, invalid 5, hence it is evident that adverse reaction 0) it is apparently higher than control group (70.
59%, it is almost recovered 26, effective 2, effective 8, invalid 15, hence it is evident that adverse reaction 0, P < 0. is 05).The present invention controls
The Chinese medicine composition cure rate for treating cerebral arterial thrombosis is higher, and without obvious adverse reaction.
Claims (10)
1. a kind of pharmaceutical composition for treating cerebral arterial thrombosis, including Dioscin, arasaponin, Gardenoside, different US business
Land phenol A, it is characterised in that: the parts by weight of the Dioscin are 8-15, and the parts by weight of arasaponin are 6-12, cape jasmine
The parts by weight of glycosides are 6-12, and the parts by weight of different american pokeweed root leaf and seed phenol A are 6-12.
2. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 1, it is characterised in that: the Dioscin
Parts by weight be 10-12, the parts by weight of arasaponin are 8-10, and the parts by weight of Gardenoside are 8-10, different american pokeweed root leaf and seed
The parts by weight of phenol A are 8-10.
3. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 1, it is characterised in that: the total soap of Radix Notoginseng
Glycosides the preparation method comprises the following steps: take appropriate notoginseng decoction piece, it is dry to after constant weight, crush, then three times with distillation water boiling and extraction, merge
Decocting liquid, being concentrated into relative density is 1.10g/ml, is filtered, and macroporous absorbent resin on filtrate passes through chromatography with flow velocity 3-5BV/h
Column (BV column volume) washes at least ten column volume when absorption reaches equilibrium state, water-solubility impurity is removed, finally, using 5-
60% ethanol water isocratic elution of 8 times of column volumes, flow velocity are 1-2 BV/h, collect eluent, are concentrated into no alcohol taste, 50-60
DEG C vacuum drying, obtain thick arasaponin.
4. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 3, it is characterised in that: take the total soap of thick Radix Notoginseng
Glycosides powder 100mg, is dissolved in 60% ethanol water, and the arasaponin solution that concentration is 2mg/ml is made, flows through cationic friendship
It changes resin column and connects into anion-exchange resin column, flow velocity is 1-2 BV/h by chromatographic column, repeats elution 3-5 times, most
It is eluted afterwards with 60% ethanol water of 10 times of column volumes, collects eluent and be concentrated into no alcohol taste, 50-60 DEG C of vacuum drying obtains
The arasaponin of high-purity.
5. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 3, it is characterised in that: the cation
Exchanger resin is D72, any one in anion exchange resin D201, D296, D280, Dt, Gt, Ds.
6. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 3, it is characterised in that: the cation
The ratio of exchanger resin and anion exchange resin is 1 ︰ 1.
7. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 1, it is characterised in that: the composition can
One or more of solution, tablet, capsule, pill and granule is made.
8. the pharmaceutical composition for the treatment of cerebral arterial thrombosis according to claim 1, it is characterised in that: the composition is also
Including the auxiliary material in pharmaceutically allowed band, the auxiliary material includes binder, filler, disintegrating agent, lubricant in tablet, liquid
Preservative, antioxidant, corrigent, aromatic, cosolvent, emulsifier, solubilizer, osmotic pressure regulator in body preparation etc., with
And auxiliary material used in capsule, pill and granule.
9. pharmaceutical composition according to claim 1 is in the application for the treatment of cerebral arterial thrombosis.
10. application according to claim 8, it is characterised in that: described pharmaceutical composition is for the drug with anti-cerebral ischemia
Use in conjunction, for improving cerebral arterial thrombosis therapeutic effect caused by hypertension, hyperlipidemia, diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811304617.7A CN109172624A (en) | 2018-11-04 | 2018-11-04 | A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811304617.7A CN109172624A (en) | 2018-11-04 | 2018-11-04 | A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109172624A true CN109172624A (en) | 2019-01-11 |
Family
ID=64941618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811304617.7A Pending CN109172624A (en) | 2018-11-04 | 2018-11-04 | A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109172624A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116889582A (en) * | 2023-05-10 | 2023-10-17 | 云南云龙制药股份有限公司 | Application of pseudo-ginseng granule active ingredient composition in preparation of medicines for treating ischemic cerebral apoplexy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476891A (en) * | 2003-06-19 | 2004-02-25 | 北京中医药大学 | Chinese medicine composition for curing apoplexy and its preparation method |
| CN101229207A (en) * | 2008-01-30 | 2008-07-30 | 南开大学 | Decolor refined technology of notoginseng total saponin duolite method |
-
2018
- 2018-11-04 CN CN201811304617.7A patent/CN109172624A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476891A (en) * | 2003-06-19 | 2004-02-25 | 北京中医药大学 | Chinese medicine composition for curing apoplexy and its preparation method |
| CN101229207A (en) * | 2008-01-30 | 2008-07-30 | 南开大学 | Decolor refined technology of notoginseng total saponin duolite method |
Non-Patent Citations (2)
| Title |
|---|
| YOSHIYASU FUKUYAMA ET AL.: "Structures of Americanol A and Isoamericanol A Having a Neurotrophic Property from the Seeds of Phytolacca americana", 《CHEM.PHARM.BULL.》 * |
| 沈甜 等: "栀子苷与薯蓣皂苷对脑缺血再灌注大鼠急性期和恢复早期炎性损伤机制研究", 《陕西中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116889582A (en) * | 2023-05-10 | 2023-10-17 | 云南云龙制药股份有限公司 | Application of pseudo-ginseng granule active ingredient composition in preparation of medicines for treating ischemic cerebral apoplexy |
| CN116889582B (en) * | 2023-05-10 | 2024-04-16 | 云南云龙制药股份有限公司 | Application of composition in preparation of medicines for treating ischemic cerebral apoplexy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
| CN102861287A (en) | Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot and preparation method thereof | |
| KR100327894B1 (en) | Hypertension-treatment and colestearol-depressant composition comprising extract from mixture of panax notoginseng and salvia miltiorrhiza and method of preparing the same | |
| CN103495063A (en) | Traditional Chinese medicine preparation for treating icteric hepatitis as well as preparation method thereof | |
| CN104906251A (en) | Traditional Chinese medicine compound combination with diabetes treating effect and preparation method and application thereof | |
| CN109172624A (en) | A kind of pharmaceutical composition and its application for treating cerebral arterial thrombosis | |
| KR101210405B1 (en) | Radix salviae miltiorrhizaeextract and composition thereof for the treatment of the aspirin resistance diseases | |
| CN101940605B (en) | Chinese loropetalum leaf total flavonol extract and medical application thereof | |
| CN102846824A (en) | Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN106938048A (en) | A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN108671074B (en) | Ginkgo leaf and wolfberry compound oral liquid for preventing and/or treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN104027525A (en) | Drug for treatment of ischemic heart disease, preparation method and application thereof | |
| CN103830495A (en) | Traditional Chinese medicine composition for treating fundus hemorrhage caused by diabetic retinopathy and preparation method thereof | |
| CN100418534C (en) | Traditional Chinese medicine active part compound preparation for curing cardiac and cerebral vascular diseases and its preparing method | |
| CN103768349B (en) | Application in preparation treatment cerebrovascular and relevant disease medicine for the four taste Fructus cinnamomi camphorae preparations | |
| CN109771567A (en) | A kind of formula of Chinese herbal medicine supporting vital QI and dispersing blood stasis toxin expelling tumour | |
| CN101716253B (en) | Chinese medicinal preparation containing panax notoginseng, and preparation method thereof | |
| CN104587047B (en) | A kind of Chinese medicine composition for being used to treat cardiovascular and cerebrovascular disease | |
| CN114767816B (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
| CN116327825B (en) | A Chinese medicinal composition for treating cardiovascular diseases, and its preparation method | |
| CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
| CN108478706A (en) | It is a kind of to protect cardiovascular composition and preparation method thereof | |
| CN108743654B (en) | Traditional Chinese medicine composition for treating ischemic heart disease and preparation method and application thereof | |
| CN107661422B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 602-15, building a, vitality Business Plaza, 185 jumao street, Yuanhe street, Xiangcheng District, Suzhou City, Jiangsu Province Applicant after: Suzhou Bozhu Biotechnology Co., Ltd Address before: 200082 room 1105, Wu Dong Road, Yangpu District, Shanghai, 1105 Applicant before: SHANGHAI BOGUI CULTURE COMMUNICATION Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190111 |
|
| WD01 | Invention patent application deemed withdrawn after publication |